Member Info for Gunner68

Hi August are you sure 1802 can go into patients just on 1801 safety results ? Do we not need to do the toxicology studies first ?

GLA

Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week 52

Priovant plans to continue progressing the program in indications outside of Systemic Lupus Erythematosus (SLE) given the drug’s favorable safety and tolerability profile, six other positive phase 2 studies, and active arm performance in this study

Hi SOG I had a look at this over Xmas and noted Priovant and Riovant but with cash to invest let’s hope safety is top notch and hopefully we will get investment after ph1a results

GLA

No apologies needed PCS hope you had a great weekend , yes it is frustrating and I don’t get the mms making a market this is being manipulated to be below a penny which we basically are is a disgrace no matter what any spin anyone puts on it I’ve gone on about 1802 and again something the BOD should be being proactive about, time will tell, if they made what they say is the right decision with RF we will definately find out in the next few months with the next large tranche of shares being released unless we get a decent upfront payment from 737 or will it be a red herring again the BOD didn’t have any say-on something we have 27.5 pc ownership of or will the data data data from ph1a save the day and get us a deal

GLA

Maybe they would of when there shares were worth millions and now just 500k a massive hit to them but could all show faith and invest there is no closed period as they don’t know the results of the trial as it’s totally blind

Come on BOD hands in pocket and show some faith in the company

GLA

Basil we should not be waiting a year for this to be decided I never got to ask my question at the AGM as time bound just because the trial will finish will not bring shareholder value we have no pipeline apart from 1801 . 1802 on the shelf no money ,737 out of our hands Imho there was better deals to be had and big investors willing to get on board but this route wasn’t taken how many would take a low offer now if an offer came in ? Remember there’s a lot of poor souls who invested at a lot higher than I’m sure we have and must be sitting at the most a near 90pc loss

Will they ever see shareholder value and one of the biggest misleading bits of misinformation was getting funding from agile which we was never going to achieve

GLA

Potnak apart from the trial is completed and then we are waiting months for the results to be analysed surely this could do no harm

GLA

Potnak apart from the trial is completed and then we are waiting months for the results to be analysed surely this could do no harm

GLA

We consolidated to make us more attractive and to stop manipulation of the share price it’s going really well so far what’s going to happen once the trial has finished and we’re waiting for months again for news then ? Looks like who called 20p could be right unless 737 delivers a big upfront payment nothing happening with 1802 maybe we are a one trick pony at the moment

GLA

PS I think the AGM should be longer to at least get some of the submitted questions answered and challenged if needed and allow investors to speak to all the BOD if they needed to it would of been nice to ask a few questions to the scientists and congratulate them on what they have achieved so far and was able to talk to Stephen Parker along with other investors

GLA

Congratulations Clive and hope you have a very long and enjoyable retirement hopefully Sar can come good for everyone and within the next 12-18 months

PCS I was impressed with Q17 reply actually gave all info on what they were looking for in the ph1a trail and something I think would be beneficial on the actual Sar website linked with 1801

Dissapointed with Q8 when they say about 737/1802

.Even at the AGM it came across that 1802 which I’m sure would add value is not getting progressed this year due to lack of financial funding , why they carnt look to raise and get the tox done I carnt phathom out . With the potential of what it could bring surely there is someone who would look to take it forward and get in early

GLA

It doesn’t matter what they call it as we have no control over 737 but would be interesting to know how big the 1st milestone payment would be after the initial 500k signing fee is . Let’s hope it’s a decent size and comes pretty quick

GLA

And in another 6 months we ll have to be looking for funding for 2025 let’s hope we don’t just take the easy option like we did and get robbed by RF maybe the predictions of 20p weren’t wrong and could be the real bottom of the share

GLA

Come on SAR let’s get the replies to the Q&A from the AGM out

GLA

Andy Plump, M.D., Ph.D., Takeda’s head of R&D and a member of the company's board, detailed how competitive the dealmaking process was in an interview on the sidelines of this year’s J.P. Morgan Healthcare Conference. In fact, “almost every biopharmaceutical company” was in the mix for the asset at some point.

Which means a lot missed out and are they still on the hunt

GLA

I looked at this SOG and I noticed it said excluding the China region I’m just wondering (wild guess )if it’s because we have the patent granted for China with our tyk2 jak 1 may be totally out mind

GLA

Does anyone know if Hangzhou s tyk2 jak1 TLL-018 has been patented in China ? And is this one we can compare against . Ph2 data out mid year for psoriasis Have tried to find out to no avail

GLA

As mentioned before also anogenital was another one

GLA

Roivant’s Matt Gline on raising capital and biotech’s outlook for 2024

Following a $7 billion deal with Roche, the chief executive says Roivant is focused on reinvesting that cash infusion into R&D

A good read

GLA

Https://aacrjournals.org/clincancerres/article/29/2/331/713982/A-Phase-I-II-Trial-of-Oral-SRA737-a-Chk1-Inhibitor

GLA

Hi silver hope you had a great Xmas and New year at least they are still there I was in Desire the famous oil to water company fingers crossed for Sareum

GLA